BIOHIT OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.995 EUR | +0.50% |
|
-0.75% | +5.84% |
| Apr. 15 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
| Feb. 14 | Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 15.3M 16.65M | Sales 2025 * | 17.4M 18.93M | Capitalization | 30.12M 32.77M |
|---|---|---|---|---|---|
| Net income 2024 * | 1M 1.09M | Net income 2025 * | 2M 2.18M | EV / Sales 2024 * | 1.42 x |
| Net cash position 2024 * | 8.4M 9.14M | Net cash position 2025 * | 10M 10.88M | EV / Sales 2025 * | 1.16 x |
| P/E ratio 2024 * |
15.3
x | P/E ratio 2025 * |
15.3
x | Employees | 46 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.47% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.50% | ||
| 1 week | -0.75% | ||
| Current month | -0.75% | ||
| 1 month | -2.68% | ||
| 3 months | -0.25% | ||
| 6 months | +3.10% | ||
| Current year | +5.84% |
1 week
1.97
2.02
1 month
1.972.07
Current year
1.802.10
1 year
1.712.22
3 years
1.052.54
5 years
1.054.30
10 years
1.057.17
| Managers | Title | Age | Since |
|---|---|---|---|
Jussi Hahtela
CEO | Chief Executive Officer | 51 | 21-06-03 |
Jussi Sorvo
DFI | Director of Finance/CFO | 34 | 20-12-31 |
Panu Hendolin
CTO | Chief Tech/Sci/R&D Officer | 53 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 56 | 23-06-13 | |
| Founder | 81 | 87-12-31 | |
| Director/Board Member | 73 | 19-04-23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-15 | 1.995 | +0.50% | 6 798 |
| 24-05-14 | 1.985 | +0.25% | 8,561 |
| 24-05-13 | 1.98 | -1.00% | 12,788 |
| 24-05-10 | 2 | -0.50% | 15,612 |
| 24-05-08 | 2.01 | +0.50% | 5,604 |
Delayed Quote Nasdaq Helsinki, May 15, 2024 at 11:18 am EDT
More quotes
Biohit Oyj is a Finland-based company engaged in the development, manufacture and marketing of diagnostic tests and analysis systems. The Company operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. It provides blood-sample examination based on GastroPanel for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, as well as the ColonView examination for the early detection of fecal occult intestinal bleeding, which indicates a risk of colorectal cancer. The Companyâs products are used in hospitals, healthcare centers and research institutions. It operates primarily in Europe and Asia. Furthermore, the Company is a parent of Biohit Healthcare Ltd, Biohit Healthcare Srl, Oy Finio Ab, and Vantaan Hienomekano Oy, among others.
Sector
Office Equipment
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.985
EUR
Average target price
2.4
EUR
Spread / Average Target
+20.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.84% | 32.58M | |
| +9.89% | 8.35B | |
| -0.87% | 4.76B | |
| -4.59% | 2.95B | |
| +7.35% | 2.14B | |
| -28.01% | 1.11B | |
| -5.13% | 836M | |
| -24.67% | 749M | |
| -22.92% | 674M | |
| -56.53% | 625M |
- Stock Market
- Equities
- BIOBV Stock
